The Latest Monoclonal Antibody Industry Statistics Explained
The monoclonal antibodies market size was valued at USD 115.2 billion in 2020.
The statistic “The monoclonal antibodies market size was valued at USD 115.2 billion in 2020” indicates the total market worth of monoclonal antibodies, a type of therapeutic protein used in treating various diseases. This value reflects the revenue generated from the sales of monoclonal antibodies products worldwide during the year 2020. The significant market size highlights the growing demand for monoclonal antibodies in healthcare and pharmaceutical industries, as they continue to play a crucial role in the treatment of conditions such as cancer, autoimmune diseases, and infectious diseases. The substantial market value suggests a high level of investment and research in developing and commercializing these biopharmaceutical products, showcasing their importance and potential within the global healthcare market.
It is projected to expand at a compound annual growth rate (CAGR) of 14.6% from 2021 to 2028.
The statistic implies that the subject, such as a market, industry, or technology, is expected to experience significant growth over the specified timeframe. Specifically, it is projected to grow at a compound annual growth rate (CAGR) of 14.6% from 2021 to 2028. This indicates that the subject is anticipated to increase its value or scale by an average of 14.6% each year over the specified period. This growth rate suggests a strong upward trajectory and indicates potential opportunities for investment, development, or strategic decision-making during this time frame.
The U.S. monoclonal antibodies market accounted for the highest market share, 45.5% in 2020.
The statistic “The U.S. monoclonal antibodies market accounted for the highest market share, 45.5% in 2020” indicates that out of all the countries analyzed or all the markets in the global pharmaceutical industry for monoclonal antibodies, the United States held the largest portion of market sales at 45.5% in the year 2020. This suggests that the demand for monoclonal antibodies in the U.S. was particularly strong compared to other countries or regions during that period, potentially driven by factors such as robust research and development activities, favorable regulatory environment, and high healthcare expenditure. This statistic highlights the significant role that the U.S. market plays in the global monoclonal antibodies industry and underscores the country’s importance as a key player in this sector.
The oncology monoclonal antibodies market size was valued at $45 billion in 2019.
The statistic “The oncology monoclonal antibodies market size was valued at $45 billion in 2019” suggests that the total worth of sales in the market for monoclonal antibodies used in oncology treatments during the year 2019 amounted to $45 billion. This figure reflects the significant economic impact and demand for monoclonal antibody therapies in the field of oncology, indicating a substantial market size and growing interest in these specialized treatments. As a key marker for the industry’s financial performance, this statistic reveals the substantial investment and spending by pharmaceutical companies, healthcare providers, and patients in oncology monoclonal antibody products for cancer treatment.
Cancer monoclonal antibodies dominated the oncology market, with $30 billion in 2019.
The statistic “Cancer monoclonal antibodies dominated the oncology market, with $30 billion in 2019” indicates that monoclonal antibodies designed to target cancer cells were the leading category of drugs in the field of oncology in terms of both revenue and market share in the year 2019. This figure, amounting to $30 billion, highlights the significant impact and widespread utilization of monoclonal antibodies in the treatment of cancer. It suggests that these specialized drugs were preferred by healthcare providers and patients for their effectiveness and therapeutic value, potentially signaling a shift towards personalized and targeted treatments in the oncology field.
Monoclonal antibodies are forecasted to account for 26.5% of the global biopharmaceutical market by 2024.
This statistic indicates that monoclonal antibodies are projected to have a significant presence in the global biopharmaceutical market, representing approximately 26.5% of the market share by the year 2024. Monoclonal antibodies are a type of biopharmaceutical that are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. The forecasted growth in the market share of monoclonal antibodies suggests a strong demand for these therapeutic agents in the coming years, potentially driven by advancements in biotechnology, increased research and development efforts, and the approval of new monoclonal antibody drugs. This statistic highlights the growing importance of monoclonal antibodies in the biopharmaceutical industry and their potential impact on healthcare delivery and patient outcomes.
Monoclonal antibodies are anticipated to witness about 60% of the growth in the biopharma industry between the years 2018-2024.
The statistic suggests that monoclonal antibodies are expected to significantly drive the growth of the biopharma industry, accounting for approximately 60% of the overall growth between 2018 and 2024. Monoclonal antibodies are specialized proteins that can target specific antigens in the body, making them effective in treating various diseases such as cancer, autoimmune disorders, and infectious diseases. The anticipated growth highlights the growing demand for innovative biopharmaceutical products and the increasing recognition of the therapeutic potential of monoclonal antibodies in addressing complex medical conditions. This statistic underscores the potential economic and healthcare impact of monoclonal antibodies in shaping the future of the biopharma industry.
In terms of regional segmentation, North America held the biggest share of the global monoclonal antibodies market, about 42.4% in 2018.
The statistic indicates that North America accounted for the largest proportion of the global market for monoclonal antibodies in 2018, with a share of approximately 42.4%. This implies that the demand for monoclonal antibodies, a type of therapeutic protein used in various medical treatments, was highest in North America compared to other regions such as Europe, Asia-Pacific, and Latin America. Factors contributing to this larger market share in North America could include advanced healthcare infrastructure, favorable regulatory environment, higher healthcare expenditures, and extensive research and development activities in the pharmaceutical and biotechnology sectors. The dominance of North America in the global monoclonal antibodies market highlights the region’s significance as a key player in the pharmaceutical industry.
The Asian monoclonal antibody therapy market is expected to observe the fastest CAGR of around 9.2% during 2021-2027.
This statistic indicates the projected Compound Annual Growth Rate (CAGR) for the Asian monoclonal antibody therapy market over the period from 2021 to 2027. A CAGR of 9.2% suggests that this market segment is anticipated to experience significant growth during this timeframe, outpacing other regions and segments within the healthcare industry. This indicates a promising outlook for the adoption and utilization of monoclonal antibody therapies in Asia, with potential implications for advancements in healthcare, increased investment in research and development, and improved access to innovative medical treatments. The forecasted rapid growth in the Asian monoclonal antibody therapy market underscores the region’s increasing importance in the global healthcare landscape and highlights opportunities for stakeholders in the industry to capitalize on this growing market trend.
The monoclonal antibody therapeutics market accounted for over a quarter of all FDA approvals in 2017.
In 2017, the monoclonal antibody therapeutics market played a significant role in the pharmaceutical industry, as it represented more than 25% of all new drug approvals granted by the U.S. Food and Drug Administration (FDA). This statistic highlights the growing importance and popularity of monoclonal antibody treatments in the field of medicine. Monoclonal antibodies are engineered to target specific markers on cells, making them highly effective for treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The large number of FDA approvals in this market suggests a strong focus on research and development in this area, as well as the increasing acceptance and adoption of monoclonal antibody therapies by healthcare providers and patients.
There were nearly 570 monoclonal antibody products in clinical studies globally by the end of 2018.
The statistic indicating there were nearly 570 monoclonal antibody products in clinical studies globally by the end of 2018 highlights the significant growth and interest in utilizing monoclonal antibodies for therapeutic purposes. Monoclonal antibodies are engineered to target specific antigens, making them valuable tools in drug development, particularly for treating various diseases such as cancer, autoimmune disorders, and infectious diseases. The large number of monoclonal antibody products in clinical trials underscores their potential in advancing medicine and improving patient outcomes through targeted and personalized treatments. The diversity of monoclonal antibody products being studied also hints at the wide range of potential applications and the ongoing advancements in this field of biopharmaceutical research.
Europe’s monoclonal antibody market size will register a CAGR of nearly 6.3% between 2020-2026.
This statistic implies that Europe’s monoclonal antibody market is projected to experience a Compound Annual Growth Rate (CAGR) of approximately 6.3% over the period from 2020 to 2026. The CAGR represents the average annual growth rate of the market size during this timeframe. A CAGR of 6.3% suggests a significant and steady increase in the market value of monoclonal antibodies in Europe, indicating growth opportunities for businesses operating in this sector. This growth rate can be influenced by factors such as increased research and development activities, advancements in technology, and rising demand for monoclonal antibody therapies in treating various diseases.
Monoclonal Antibodies accounted for 70% of the top ten best-selling drugs in Japan in 2019.
The statistic “Monoclonal Antibodies accounted for 70% of the top ten best-selling drugs in Japan in 2019” indicates that a majority of the highest-selling pharmaceutical products in Japan for that year were monoclonal antibodies. Monoclonal antibodies are a type of biopharmaceutical that can target specific cells or proteins in the body, making them effective for treating various diseases such as cancer and autoimmune disorders. This statistic suggests that monoclonal antibodies have gained significant popularity and market share within the pharmaceutical industry in Japan, possibly due to their effectiveness and increasing acceptance in medical practice.
Monoclonal antibody-based medicines account for seven of the top ten best-selling drugs globally.
The statistic indicates that a significant proportion of the top-selling drugs worldwide are monoclonal antibody-based medicines. Monoclonal antibodies are a type of biological therapy designed to target specific molecules within the body, such as disease-causing proteins. The fact that seven out of the top ten best-selling drugs are monoclonal antibody-based medicines highlights their effectiveness and widespread use in treating various health conditions. This statistic also suggests that pharmaceutical companies are investing heavily in the development and production of these types of drugs due to their high demand and therapeutic value in modern healthcare.
Antibody-drug conjugates in the global maAb market are predicted to grow at a CAGR of 21.7% till 2023.
This statistic indicates that the market for antibody-drug conjugates (ADCs) within the global monoclonal antibody (mAb) market is projected to experience significant growth at a compound annual growth rate (CAGR) of 21.7% until the year 2023. Antibody-drug conjugates are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. The forecasted high CAGR suggests a growing demand for these innovative therapies, potentially driven by advancements in technology, increasing prevalence of cancer, and the need for more effective and personalized treatment options. This growth trend highlights the potential for significant market expansion and opportunities within the ADC segment of the global mAb market in the coming years.
The cancer monoclonal antibody market will reach around $138 billion revenues globally by 2027.
The statistic that the cancer monoclonal antibody market is projected to reach around $138 billion in revenues globally by 2027 suggests a significant growth opportunity for the industry. Monoclonal antibodies are a type of targeted therapy that have shown promise in the treatment of various types of cancer, and the projected market growth reflects increasing investments in research and development as well as a growing demand for more personalized and effective cancer treatments. This statistic underscores the potential for continued advancements in the field of cancer immunotherapy and signals a shift towards more innovative and tailored approaches to cancer treatment in the coming years.
Conclusion
The statistics outlined in this blog post highlight the profound impact of the monoclonal antibody industry on healthcare and biopharmaceutical sectors. By shedding light on the market size, growth trends, and key players in the industry, it is evident that monoclonal antibodies continue to revolutionize medical treatments and drive innovation. These insights underscore the importance of staying informed about the rapidly evolving landscape of monoclonal antibody therapeutics.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.bccresearch.com
2. – https://www.www.ncbi.nlm.nih.gov
3. – https://www.www.chemdiv.com
4. – https://www.www.technologynetworks.com
5. – https://www.www.globenewswire.com
6. – https://www.www.fortunebusinessinsights.com
7. – https://www.www.pharmaceutical-technology.com
8. – https://www.www.thermofisher.com
